Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453332 | 0.79 | MMP1 (0.51) | MMP1KIF11HSD11B1ALDH1A1L3MBTL1 | |
| SCHEMBL619004 | 0.78 | LMNA (0.41) | ALDH1A1KMT2ACA2CYP3A4CYP2C9 | |
| SCHEMBL64436 | 0.78 | ALDH1A1 (0.63) | ALDH1A1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2587720 | 0.78 | ALDH1A1 (0.44) | MMP1ALDH1A1KMT2ACA2CYP3A4 | |
| SCHEMBL28051 | 0.78 | PSIP1 (0.47) | MMP1HSD11B1ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL28865930 | 0.75 | ALDH1A1 (0.38) | MMP1ALDH1A1KMT2ACA2CYP3A4 | |
| SCHEMBL28932041 | 0.75 | ALDH1A1 (0.38) | MMP1ALDH1A1KMT2ACA2CYP3A4 | |
| SCHEMBL28166558 | 0.75 | ALDH1A1 (0.59) | ALDH1A1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5664985 | 0.75 | HTR6 (0.47) | MMP1HSD11B1ALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL1282212 | 0.75 | MMP1 (0.55) | MMP1KIF11HSD11B1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024110477-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | WO | claimed |
| WO-2024042448-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | GRANULES INDIA LIMITED (IN) | 2024-02-29 | — | — | WO | claimed |
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2023-09-28 | — | — | US | claimed |
| EP-4206205-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | Primegene (Beijing) Co., Ltd. (CN) | 2023-07-05 | — | — | EP | claimed |
| EP-3985008-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | Incyte Holdings Corporation (US) | 2022-04-20 | — | — | EP | claimed |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | claimed |
| EP-3398952-B1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-07-14 | — | — | EP | claimed |
| EP-3473625-B1 | PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-06-02 | — | — | EP | claimed |
| US-10766901-B2 | Preparation method for chiral pyrrolopyrimidine compound | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-08 | — | — | US | claimed |
| US-10562904-B2 | Synthesis process of ruxolitinib | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-02-18 | — | — | US | claimed |
| US-20160347734-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2016-12-01 | — | — | US | claimed |
| WO-2016035014-A1 | PROCESSES FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-03-10 | — | — | WO | claimed |
| EP-2964650-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | Incyte Corporation (US) | 2016-01-13 | — | — | EP | claimed |
| US-8987443-B2 | Processes and intermediates for making a JAK inhibitor | INCYTE CORPORATION (US) | 2015-03-24 | — | — | US | claimed |
| US-8859490-B2 | Peptide nucleic acid monomers and oligomers | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-10-14 | — | — | US | claimed |
| WO-2014138168-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2014-09-12 | — | — | WO | claimed |
| US-20140256941-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2014-09-11 | — | — | US | claimed |
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-03-15 | — | — | US | claimed |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHONOLOGICAL UNIVERSITY (SG) | 2011-10-06 | — | — | US | claimed |
| WO-2010027326-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-03-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | MMP1 4834/4885KIF11 4032/4885HSD11B1 4439/4885 |
| US-10562904-B2 | Synthesis process of ruxolitinib | JAK3, JAK1, JAK2 | MMP1 4303/4885KIF11 2413/4885HSD11B1 685/4885 |
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | DPYD, RPLP2, DHPS | MMP1 4658/4885KIF11 1748/4885HSD11B1 2017/4885 |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | MMP1 4312/4885KIF11 2263/4885HSD11B1 2157/4885 |
| US-10766901-B2 | Preparation method for chiral pyrrolopyrimidine compound | DHPS, DPYD, MPHOSPH6 | MMP1 4034/4885KIF11 1051/4885HSD11B1 110/4885 |
| US-20140256941-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | JAK1, JAK2, JAK3 | MMP1 2418/4885KIF11 3417/4885HSD11B1 2616/4885 |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | MMP1 4834/4885KIF11 4032/4885HSD11B1 4439/4885 |
| US-20160347734-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | JAK1, JAK2, JAK3 | MMP1 2418/4885KIF11 3417/4885HSD11B1 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.